NEW LIPID ESTERS OF NUCLEOSIDE MONOPHOSPHATES AND THEIR USE AS IMMUNOSUPPRESSIVE DRUGS

Abstract: The present invention is directed to new nucleoside monophosphate derivatives of lipid ester residues of general formula (I), wherein R<1> represents an optionally substituted alkyl chain having 1-20 carbon atoms; R<2> represents hydrogen, an optionally substituted alkyl chain having 1-20 carbon atoms; R<3>, R<4> and R<5> represent hydrogen, hydroxy, azido, amino, cyano, or halogen; X represents a valence dash, oxygen, sulfur, a sulfinyl or sulfonyl group; Y represents a valence dash, an oxygen or sulfur atom; B represents a purine and/or pyrimidine base; with the proviso that at least one of the residues R<3> or R<5> is hydrogen; to their tautomers and their physiologically acceptable salts of inorganic and organic acids and/or bases, as well as to processes for their preparation, and to drugs containing said compounds.

Description: New Lipid Esters of Nucleoside Monophosphates and Their Use as I unosuppressive Drugs The present invention is directed to new nucleo¬ side monophosphate derivatives of lipid ester residues of general formula (I) wherein R 1 may be a straight-chain or branched, saturated or unsaturated alkyl chain having 1-20 carbon atoms, op¬ tionally mono- or polysubstituted by halogen, C^-Cg al- koxy, C]_-Cg alkylmercapto, C^-Cg alkoxycarbonyl, C^-Cg alkylsulfinyl, or C^-Cg alkylsulfonyl groups; R 2 may be hydrogen, a straight-chain or branched, saturated or unsaturated alkyl chain having 1-20 carbon atoms, optionally mono- or polysubstituted by halogen, C -Cg alkoxy, Cτ_-Cg alkylmercapto, C]_-Cg alkoxycarbonyl, or C^-C alkylsulfonyl groups; R 3 represents hydrogen, hydroxy, azido, amino, cya- no, or halogen; R< represents hydroxy, azido, amino, cyano, or ha- logen; represents hydrogen, hydroxy, azido, amino, cya¬ no, or halogen; X represents a valence dash, oxygen, sulfur, a sulfinyl or sulfonyl group; Y is a valence dash, an oxygen or sulfur atom; B represents a purine and/or pyrimidine base of formula Ill.a-d) (IMa) (lllb) (lllc) (Hid) wherein R 6 may be hydrogen; an alkyl chain having 1-6 car¬ bon atoms, which may be substituted by halogen; an al- kenyl and/or alkinyl residue having 2-6 carbon atoms, optionally substituted by halogen; or halogen; R 6 ' may be a hydrogen atom or a benzyl or phenylthio residue; R 7 may be hydrogen; an alkyl chain having 1-6 car¬ bon atoms, which may be substituted by halogen; or halo¬ gen; R 8 may be hydrogen, an alkyl chain having 1-6 car¬ bon atoms, halogen, or a hydroxy or an amino group; R^ may be hydrogen, an amino group or a halogen atom; and R 1 ^ may be hydrogen, halogen, mercapto, hydroxy, Cτ_-Cg alkoxy, C]_-Cg alkylmercapto, or an amino group which may be mono- or disubstituted by C 1 -Cg alkyl, Ci-Cg alkoxy, hydroxy-C2~Cg alkyl, and/or C β -C cyclo- alkyl, aryl, hetaryl, aralkyl, or hetarylalkyl groups, optionally substituted at the aryl or hetaryl residue by one or more mercapto, hydroxy, C^-C alkoxy, or Cη ^ -Cg alkyl groups or halogen; or C2~Cg alkenyl optionally substituted by mono- or dialkyl or alkoxy groups; with the proviso that at least one of the residues R 3 or R^ is hydrogen; to their tautomers and their physiologically accept¬ able salts of inorganic and organic acids and/or bases, as well as to processes for their preparation, and to drugs containing said compounds. As these compounds of general formula I contain asymmetric carbon atoms, the invention is likewise di¬ rected to all the optically active forms and racemic mix¬ tures of said compounds. J. Biol. Chem. 265. 6112 (1990), and EP 0,350,287 describe preparation and use of liponucleotides as anti¬ viral drugs. Therein, however, only dimyristoylphosphati- dyl and dipalmitoylphosphatidyl residues coupled to fami¬ liar nucleoεides such as AZT (azidothymidine) and ddC (2' , 3' -dideoxycytidine) have been examined and synthesi¬ zed, including their fatty acid ester structure. J. Med. Chem. 3_3, 1380 (1990) , describes nucleoside conjugates of thioether lipides with cytidine diphosphate, which have antitumor activity and might find use in oncol¬ ogy. Chem. Pharm. Bull. 3_6, 209 (1988), describes 5'-(3- sn-phosphatidyl)nucleosides having antileukemic activity, as well as their enzymatic synthesis from the correspon¬ ding nucleosides and phosphocholines in the presence of phospholipase D with transferase activity. Similarly, J. Med. Chem. . 34 . , 1408 (1991) , describes nucleoside conjuga¬ tes having anti-HIV 1 activity, which are substituted by methoxy or ethoxy in sn-2 position of the lipid portion. The patent application WO 92/03462 describes thioether li¬ pid conjugates having antiviral activity, particularly for treating HIV infections. The compounds of the present invention have valuable pharmacological properties. In particular, they are suitable in therapy and prophylaxis of malignant tumors such as malignancies, neoplasms, carcinomas, sarcomas, or leukemias in tumor therapy. In addition, the compounds ex¬ hibit immunosuppressive activity and therefore, they may be employed in the therapy of organ-specific or generali¬ zed auto-immune diseases such as rheumatoid arthritis, sy¬ stemic lupus erythematosus, chronic graft vs. host di¬ sease, multiple sclerosis, etc., or in preventing alloge- nic or semiallogenic graft rejection, e.g., kidneys, li¬ ver, lungs, - 3 - heart, etc.. Furthermore, the compounds have antiviral, anti-retroviral or anti-oncogenic activity and thus, are also suitable in prophylaxis and therapy of viral and on- cogenic-induced/caused diseases (such as AIDS etc.) . Com¬ pared to compounds hitherto employed in treatment of ma¬ lign tumors, the compounds according to the invention have enhanced efficacy or lower toxicity and thus, have a wider therapeutic range. For this reason, they are advantageous in that the administration of drugs containing these com¬ pounds may be conducted continuously over a prolonged pe¬ riod of time, and withdrawal of the preparation or inter¬ mittent administration, which frequently has been routine with cytostatic agents hitherto employed in tumor therapy or, due to their undesirable side-effects, has been neces¬ sary, can be avoided. The compounds according to the invention do not suffer from these drawbacks. Their action is immunosup- pressive or antitumoral, without being unspecifically cytotoxic in pharmacologically relevant doses. Similarly, the compounds of the present inven¬ tion and their pharmaceutical formulations may be employed in combination with other drugs for the treatment and prophylaxis of the diseases mentioned above. Examples of these further drugs involve agents such as, e.g., mitosis inhibitors such as colchicine, mitopodozid, vinblastine, alkylating cytostatic agents such as cyclophosphamide, melphalan, myleran or cisplatin, antimetabolites such as folic acid antagonists (methotrexate) and antagonists of purine and pyrimidine bases (mercaptopurine, 5-fluorouridine, cytarabin) , cytostatically active anti¬ biotics such as anthracyclines (e.g., doxorubicin, daunorubicin) , hormones such as fosfestrol, tamoxifen, other cytostatically/cytotoxically active chemotherapeutic agents and other immunosuppressive drugs (such as cy- closporines, FK 506, rapamycines, desoxyspergualin, etc.). Above all, possible salts of the compounds of general formula I are the alkali, alkaline earth and am¬ monium salts of the phosphate group. Preferred as the al¬ kali salts are lithium, sodium and potassium salts. Pos¬ sible as the alkaline earth salts are magnesium and calcium, in particular. According to the invention, am¬ monium salts are understood to be those containing the ammonium ion which may be substituted up to four times by alkyl residues having 1-4 carbon atoms, and/or aralkyl re¬ sidues, preferably benzyl residues. Here, the subεtituents may be the same or different. The compounds of general formula I may contain basic groups, particularly amino groups, which may be con¬ verted to acid addition salts by suitable inorganic or or¬ ganic acids. To this end, possible as the acids are, in particular: hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, fumaric acid, succinic acid, tar- taric acid, citric acid, lactic acid, maleic acid, or methanesulfonic acid. In the general formula I, R 1 preferably re¬ presents a straight-chain alkyl group which may be further substituted by a C^-Cg alkoxy or a C^-Cg al¬ kylmercapto group. More specifically, R 1 represents a nonyl, decyl, undecyl, dodecyl, tridecyl, or tetradecyl group. Preferably, methoxy, ethoxy, butoxy, and hexyloxy groups are possible as the C^-Cg alkoxy substituents of R 1 . In case R 1 is substituted by a C^-Cg alkylmercapto residue, this is understood to be the methylmercapto, ethylmercapto, propylmercapto, butylmercapto, and hexyl- mercapto residue, in particular. Preferably, R 2 represents a straight-chain c 8 " c 1 5 alkyl group which may be further substituted by a C^-Cg alkoxy or a C^-Cg alkylmercapto group. More speci- fically, R 2 represents an octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, or tetradecyl group. Preferably, me- thoxy, ethoxy, propoxy, butoxy, and hexyloxy groups are preferable as the C^-C alkoxy substituents of R 2 . In case R 1 is substituted by a C^-Cg alkylmercapto residue, this is understood to be the methylmercapto, ethylmercapto, butylmercapto, and hexylmercapto residue, in particular. Preferably, X is sulfur, sulfinyl or sulfonyl, and Y is oxygen. Similarly, compounds are preferred, wherein X and Y represent a valence dash, R 2 is hydrogen, and R 1 re¬ presents a C 1 -C2o alkyl chain optionally substituted by Cη ^ -Cg alkoxy or C^-Cg alkylmercapto. Preferably, R 5 represents hydrogen, azido, cyano or halogen, such as fluorine, chlorine or bromine. Preferably, each R 3 and R 4 represent a hydroxy or a cyano or azido group, or a halogen atom, such as fluorine, chlorine, bromine or iodine, wherein the resi¬ dues may be the same or different. Particularly preferred are compounds, wherein R 5 represents a hydrogen atom and R 3 and R 4 are hydroxy, cyano, azido or fluorine. In the bases of general formula (III) the resi¬ dues R 6 and R 7 preferably represent a hydrogen atom, a methyl, trifluoromethyl, ethyl, propyl, or butyl resi¬ due, or a halogen atom, such as fluorine, chlorine, bro¬ mine or iodine, as well as an alkenyl and/or alkinyl group which may be substituted by halogen. Particularly preferred for R 6 and R 7 is a hydro¬ gen atom, the methyl, trifluoromethyl or ethyl residues, and a fluorine, chlorine or bromine atom, and/or the vinyl, propenyl, ethinyl or propinyl residues optionally substituted by halogen. Preferably, the residue R 8 is a hydrogen atom, a methyl, ethyl, propyl, or butyl residue, an amino group or a halogen atom such as fluorine, chlorine bromine or iodine, preferably chlorine or bromine. Preferably, R 10 represents a hydrogen, fluorine, chlorine or bromine atom, a C^-Cg alkoxy group, more specifically a methoxy, ethoxy, propoxy, butoxy, or hexyloxy group, a mercapto residue, a Cη ^ -Cg alkylmer¬ capto group, more specifically a methylmercapto, ethyl- mercapto, butylmercapto, or hexylmercapto group, or an amino group which may be mono- or disubstituted by a C^-C alkyl group, such as the methyl, ethyl, butyl or hexyl groups, by a hydroxy-C2~Cg alkyl group, such as the hydroxyethyl, hydroxypropyl, hydroxybutyl, or hydroxyhexyl groups, by a C3-Cg cycloalkyl residue, such as the cyclopropyl, cyclopentyl or cyclohexyl residues, by aryl, preferably phenyl, by an aralkyl residue, such as, in particular, benzyl optionally substituted by one or more hydroxy or methoxy groups, by C^-Cg alkyl groups, such as the methyl, ethyl, propyl, butyl, or he¬ xyl groups, or by halogen atoms, such as fluorine, chlo¬ rine or bromine. Similarly, the amino group may be sub¬ stituted by a hetarylalkyl or hetaryl residue such as, in particular, the thienyl, furyl or pyridyl residues, for example. Preferably, the hetaryl residue is under¬ stood to be the thienylmethyl, furylmethyl or pyridyl- methyl residue. Preferably, the following nucleosides are sui¬ table as the coupling components to prepare the lipid- nucleotide conjugates of formula (I) : 6-Mercaptopurine-9-β-D-ribofuranoside 5-Fluorouridine Inosine 5-Methyluridine 2 ' , 3 ' -Didesoxy-2 ' , 3 ' -difluorothymidine 5-Chlorouridine 5-Trifluoromethyluridine 5-Ethinyluridine 5-Ethinylcytidine 5-Prop-1-enyluridine 5-Prop-2-enyluridine Adenosine Guanosine 2, 6-Diaminopurine-9-β-D-ribofuranoside 2-Amino-6-mercaptopurine-9-β-D-ribofuranoside 2-Amino-6-mercaptomethylpurine-9-β-D-ribofuranoside 2-Amino-6-chloropurine-9-β-D-ribofuranoside 2 ' -Desoxy-2 ■ -aminoadenosine 2 ' -Desoxy-2 ' -azidoadenosine 2 ' -Desoxy-2 ' -azidocytidine 2 ' -Desoxy-5-fluorouridine 2-Chloroadenosine 2-Bromoadenosine 3 ' -Desoxy-3 ' -fluoroadenosine 6-Methylmercaptopurine-9-β-D-ribofuranoside 2-Fluoroadenosine 2-Fluoro-2 ' -desoxyadenosine The compounds of general formula (I) may be pre¬ pared by reacting a compound of general formula V wherein R 1 , R 2 , X and Y have the meanings as indica¬ ted, with a compound of general formula VI wherin R 3 , R 4 , R 5 and B have the above-mentioned me¬ anings, or represent a hydroxy group protected by an oxygen protecting group familiar to the artisan, in the presence of an activating acid chloride, such as 2,4, 6-triisopropylbenzenesulfonic acid chloride, and a tertiary nitrogen base, e.g., pyridine or lutidine, in an inert solvent, such as toluene, or immediately in anhydrous pyridine, and optionally, subsequent to hydro¬ lysis, removing the oxygen protecting groups according to procedures conventional in nucleoside chemistry, or 2. reacting a compound of general formula VII H 3 (VII), wherein R 1 , R 2 , X and Y have the above-mentioned meanings, with a compound of general formula VI, wherein R 3 , R 4 , R 5 and B have the above-mentioned meanings, in the presence of phospholipase D from Streptomyces in an inert solvent such as chloroform, in the presence of a suitable buffer, and optionally, subsequent to reaction, removing the oxygen protecting groups according to procedures conventional in nucleoside chemistry. The preparation of the compounds of general for¬ mula V and VII is performed in analogy to Lipids 22, 947 (1987), and J. Med. Chem. 34,, I 377 (1991) . The preparation of the compounds of general for¬ mula VI is described, e.g., in EP-A-0,286, 028 and WO 90/08147. Some of the included nucleosides are commer¬ cially available compounds. Compounds similar to formula I are described in EP-A- 0,350,287. Therein, the corresponding 1,2-diesters of gly- cerol are described. The drugs containing compounds of formula I for the treatment of viral infections may be applied in liquid or solid forms on the intestinal or parenteral route. Here, the common application forms are possible, such as ta¬ blets, capsules, coated tablets, syrups, solutions, or suspensions. Preferably, water is used as the injection medium, containing additives such as stabilizers, solubi- lizers and buffers as are common with injection solutions. Such additives are, e.g., tartrate and citrate buffers, ethanol, complexing agents such as ethylenediaminetetr- aacetic acid and its non-toxic salts, high-molecular poly¬ mers such as liquid polyethylene oxide for viscosity con¬ trol. Liquid vehicles for injection solutions need to be sterile and are filled in ampoules, preferably. Solid car- rierε are, for example, starch, lactose, mannitol, me- thylcellulose, talc, highly dispersed silicic acids, hig¬ her-molecular fatty acids such as stearic acid, gelatine, agar-agar, calcium phosphate, magnesium stearate, animal and plant fats, solid high-molecular polymers such as po¬ lyethylene glycol, etc.. If desired, formulations suitable for oral application may include flavorings or sweeteners. The dosage may depend on various factors such as mode of application, species, age, or individual condition. Con¬ ventionally, the compounds according to the invention are applied in amounts of 0.1-100 mg, preferably 0.2-80 mg per day and per kg of body weight. It is preferred to divide the daily dose into 2-5 applications, with tablets having an active ingredient content of 0.5-500 mg being admini¬ stered with each application. Similarly, the tablets may have sustained release, reducing the number of applica¬ tions to 1-3 per day. The active ingredient content of su¬ stained-release tablets may be 2-1000 mg. The active in¬ gredient may also be administered by continuous infusions, where amounts of 5-1000 mg per day are normally suf¬ ficient. In addition to the compounds mentioned in the examples, the following compounds of formula I are possible in the meaning of the present invention: 1. (5-Chlorouridine) -5' -phosphoric acid (3-dodecylmer- capto-2-decyloxy)propyl ester 2. (5-Trifluoromethyluridine) -5' -phosphoric acid (3-do- decylmercapto-2-decyloxy)propyl ester 3. (6-Mercaptopurine-9-β-D-ribofuranoside) -5' -phospho¬ ric acid (3-dodecylmercapto-2-decyloxy)propyl ester 4. (5-Fluorouridine) -5' -phosphoric acid (3-dodecylmer- capto-2-decyloxy)propyl ester 5. (5-Prop-1-enyluridine) -5 ' -phosphoric acid (3-dode- cylmercapto-2-decyloxy)propyl ester 6. (5-Ethinylcytidine) -5 ' -phosphoric acid (3-dodecyl- mercapto-2-decyloxy)propyl ester 7. (2-Amino-6-mercaptopurine-9-β-D-ribofuranoside) -5 ' - phosphoric acid (3-dodecylmercapto-2-decyloxy)propyl ester 8. (2, 6-Diaminopurine-9-β-D-ribofuranoside) -5 ' -phospho¬ ric acid (3-dodecylmercapto-2-decyloxy)propyl ester 9. (5-Prop-2-enyluridine) -5 ' -phosphoric acid (3-dode- cylmercapto-2-decyloxy)propyl ester 10. (5-Fluorouridine) -5 ' -phosphoric acid (3-dodecylsul¬ fonyl-2-decyloxy)propyl ester 11. (5-Chlorouridine) -5 ' -phosphoric acid (3-dodecylsul- fonyl-2-decyloxy)propyl ester 12. (6-Mercaptopurine-9-β-D-ribofuranoside) -5 ' -phospho¬ ric acid (3-dodecylsulfonyl-2-decyloxy)propyl ester 13. (5-Fluorouridine) -5 ' -phosphoric acid (3-dodecyloxy- 2-decyloxy) ropyl ester 14. (6-Mercaptopurine-9-β-D-ribofuranoside) -5 ' -phospho¬ ric acid (3-dodecyloxy-2-decyloxy)propyl ester 15. (5-Fluorouridine) -5 ' -phosphoric acid (3-dodecylmer- capto-2-decylmercapto)propyl ester 16. (5-Fluorouridine) -5 ' -phosphoric acid (3-undecylmer- capto-2-undecyloxy)propyl ester 17. (5-Trifluoromethyluridine) -5 ' -phosphoric acid (3-un- decylmercapto-2-undecyloxy)propyl ester 18. (6-Mercaptopurine-9-β-D-ribofuranoside) -5 ' -phospho¬ ric acid (3-undecylmercapto-2-undecyloxy)propyl ester 19. (5-Trifluoromethyluridine) -5 ' -phosphoric acid (3- decylmercapto-2-dodecyloxy)propyl ester 20. (5-Fluorouridine) -5 ' -phosphoric acid (3-undecylmer¬ capto-2-dodecyloxy)propyl ester 21. (5-Trifluoromethyluridine) -5 ' -phosphoric acid (3-un- decylmercapto-2-decyloxy)propyl ester 22. (6-Mercaptopurine-9-β-D-ribofuranoside) -5 ' -phospho¬ ric acid (3-tetradecylmercapto-2-decyloxy)propyl ester 23. (5-Fluorouridine) -5 ' -phosphoric acid (3-tridecylmer- capto-2-decyloxy)propyl ester 24. (2-Fluoroadenosine) -5 ' -phosphoric acid (3-dodecyl- mercapto-2-decyloxy)propyl ester 25. (2-Desoxy-2-fluoroadenosine) -5 ' -phosphoric acid (3- dodecylmercapto-2-decyloxy)propyl ester 26. (6-Mercaptopurine) -9-β-D-ribofuranoside) -5 ' -phospho¬ ric acid dodecyl ester 27. (5-Fluorouridine) -5 ' -phosphoric acid hexadecyl ester 28. (5-Trifluoromethyluridine) -5 ' -phosphoric acid eico- εyl ester 29. (5-Fluorouridine) -5 ' -phosphoric acid dodecyl eεter 30. (6-Mercaptopurine-9-β-D-ribofuranoεide) -5 ' -phoεpho- ric acid dodecyl eεter Example 1 (5-Fluorouridine) -5 ' -phoεphoric acid (3-dodecylmercapto-2- decyloxy)propyl eεter 3.6 g (6.1 mmoleε) of phoεphoric acid (3-dodecylmer- capto-2-decyloxy)propyl eεter waε treated twice with 30 ml of anhydrouε pyridine and concentrated by evaporation. The reεidue waε diεεolved in 30 ml of anhydrouε pyridine, treated with 2.76 g (9.1 mmoleε) of 2, 4, 6-triisopro- pylbenzeneεulfonic acid chloride under nitrogen and εtir- red at room temperature for 30 minuteε . Then, 1.60 g (6.1 mmoleε) of 5-fluorouridine (Fluka) waε added, and the charge waε allowed to εtand under N2 for 24 hours. Hydrolysiε waε performed uεing 15 ml of water, the mix¬ ture waε εtirred for another 2 hourε at room temperature, freed from εolvent under vacuum, and εtripped twice uεing a εmall amount of toluene. The reεidue waε purified by co¬ lumn chromatography on LiChroprep ® RP-18 with a linear gradient of methanol/water 7/1 to methanol as the eluant . The yield is 3.1 g (69% of theoretical amount) ,- oil. Rf = 0.24 (CH 2 Cl 2 /MeOH 8/2) ; R f = 0.55 (CH 2 Cl 2 /MeOH/H 2 0 6.5/2.5/0.4) on Merck 5715 TLC plates, silica gel 60 F. The phoεphoric acid (3-dodecylmercapto-2-decyloxy)propyl ester was prepared as described in WO 92/03462. Example 2 (6-Mercaptopurine-9-β-D-ribofuranoεide) -5 ' -phoεphoric acid (3-dodecylmercapto-2-decyloxy)propyl eεter 6.2 g (12.5 mmoleε) of phosphoric acid (3-dodecylmer¬ capto-2-decyloxy)propyl eεter waε treated with 5.7 g (18.75 mmoleε) of 2, 4, 6-triiεopropylbenzeneεulfonic acid chloride aε described in Example 1 and subεequently with 3.55 g (11.25 mmoles) of 6-mercaptopurine-9-β-D-ribof - ranoεide and after 24 hourε, this waε hydrolyzed with wa¬ ter. Then, 2.85 g of calcium acetate in 15 ml of water was slowly dropped therein, precipitating the crude calcium εalt of the conjugate. After prolonged εtirring the pre¬ cipitate with acetone (1/10) , 6 g of an amorphouε crude product waε obtained, having 72 area -% according to HPLC. The calcium εalt waε εuεpended in 350 ml of methanol, treated with 150 g of Amberlite IR 120 in the Na + form and εtirred for 2 dayε . Thereafter, the ion exchanger waε removed, the filtrate waε evaporated, and the reεidue waε purified by column chromatography on LiChroprep ® RP-18 with a linear gradient of methanol/water 5/1 to 9/1. The fractionε containing product were evaporated in a vacuum, and the reεidue waε εtirred with acetone and dried. Yield: 3.52 g (41% of theoretical amount) . DC: R f = 0.45 (iεopropanol/butyl acetate/cone, ammo¬ nia/water 50/30/5/15) . Example 3 (6-Mercaptopurine-9-β-D-ribofuranoεide) -5' -phoεphoric acid (3-dodecylmercapto-2-decyloxy)propyl eεter εodium εalt Analogouε to Example 2, 41.4 g of phoεphoric acid (3- dodecylmercapto-2-decyloxy) ropyl eεter in 400 ml of an¬ hydrouε pyridine waε reacted with 42.9 g of 2,4, 6-triiso- propylbenzeneεulfonic acid chloride and εubεequently with 23.7 g of 6-mercaptopurine-9-β-D-ribofuranoεide. The crude calcium εalt which waε filtered by εuction after hy- drolyεiε and precipitation with 25 g of calcium acetate in 160 ml of water, waε diεtributed between 500 ml of MTB and 250 ml of 2N HCl and εtirred until completely diεεolved in the organic phase. The organic phaεe waε separated, waεhed with εaturated εodium chloride εolution and concentrated in a rotary evaporator. The reεidue waε applied onto 80 g of LiChroprep RP-18 (treat MTB εolution of crude product with RP-18, evaporate and dry) , and εeparated portion by portion in a pre-column on RP-18. Each time, a mixture of 3.7 1 of methanol, 400 ml of water, 3 ml of glacial acetic acid, and 2 g of εodium acetate served as the eluant. The fractionε containing product were combined, the deεired compound waε precipitated by adding 20 g of calcium acetate in 100 ml of water and filtered by εuction. Yield: 32 g (43% of theoretical amount) . The calcium εalt waε εuεpended in 250 ml of MTB, ex¬ tracted with 80 ml of 2N HCl by εhaking, and the organic phaεe waε waεhed twice with εaturated εodium chloride εo¬ lution. Following removal of the solvent, the reεidue waε diεεolved in 200 ml of toluene and adjuεted to pH 7 againεt a Friεcolyt electrode with 30% εodium methylate εolution. The sodium εalt waε precipitated by stirring into 200 ml of acetone, filtered by εuction and dried in a vacuum drying oven. Yield: 29 g (37% of theoretical amount) . Rf value: 0.18 (Silica gel; eluant: iεopropanol/butyl ace- tate/water/conc. ammonia 50/30/15/5) . Example 4 (6-Mercaptopurine-9-β-D-ribofuranoside) -5' -phoεphoric acid (3-dodecylmercapto-2-decyloxy)propyl eεter sodium salt Analogous to Example 3, the crude conjugate was prepared from 40 g of 6-mercaptopurine-9-β-D-ribofuranoside. The crude product waε purified by column chromatography uεing 8 g each time, on a column with DIOL phase (diameter 4 cm,- length 25 cm) (detection at 254 nra; eluant: methanol/MTB 10/4) . The applied εample had clearly disεolved in the eluant. The product-containing fractionε of the different separations were combined, evaporated and precipitated as the sodium salt from toluene and acetone as in Example 3. Yield: 64.5 g (51% of theoretical amount) . R f value: 0.85 (DIOL phase,- eluant: methanol) . INSTITUTESHEET(RULE26) Example 5 (6-Methylmercaptopurine-9-β-D-ribofuranoside) -5 ' -phoεphoric acid (3-dodecylmercapto-2-decyloxy)propyl eεter sodium εalt Analogouε to Example 1, 14.9 g of 6-methylmercaptopu- rine-9-β-D-ribofuranoεide (50 mmoleε) were reacted with the mixed anhydride prepared from 27.3 g of phoεphoric acid (3-dodecylmercapto-2-decyloxy)propyl ester and 25 g of 2, 4, 6-triiεopropylbenzeneεulfonic acid chloride in 250 ml of anhydrouε pyridine, hydrolyzed and concentrated by evaporation. Analogouε to Example 3, the crude product (HPLC: 67 area %) waε purified by chromatography on RP-18, precipitated aε the calcium εalt, and converted to the εo¬ dium salt. Yield: 15.2 g (38% of theoretical amount) . Rf value: 0.22 (Silica gel; eluant: iεopropanol/butyl ace- tate/water/conc. ammonia 50/30/15/5) . Example 6 (5-Fluorouridine) -5 ' -phoεphoric acid (3-dodecylmercapto-2- decyloxy)propyl eεter εodium εalt Analogouε to Example 1, 50 g of 5-fluorouridine waε converted to the crude conjugate, precipitated aε the cal¬ cium εalt aε deεcribed in Example 3 and εubεequent to con¬ version to the free acid, waε purified as the crude pro¬ duct by chromatography, analogous to Example 4, on a DIOL phaεe uεing methanol/MTB 10/4 as the eluant. The εodium εalt prepared as in Example 3 waε iεolated in a yield of 69%. Rf value: 0.35 (DIOL plateε; eluant: methanol/MTB 10/4) . Example 7 IC 50 values (μg/ml) for Azathioprine, 6-Mercaptopurine (6- MP) , 6-Mercaptopurinribosid, BM 92.0729 and Doxorubicin in CFU-E and CFU-GM aεεayε Thiε table εhowε the IC50 valueε (μg/ml) for Azathioprine, 6-Mercaptopurine (6-MP) and 6-Mercaptopurinriboεid in com¬ parison to the 6-Mercaptopurinriboεid ether lipid conjugate BM 92.0729 for in vitro cytotoxicity on murine bone marrow εtern cellε, including colony-forming units/erythrocyteε (CFU-E) and colony-forming unitε/granulocyteε-macrophageε (CFU-GM) . The cytoεtatic/cytotoxic compound Doxorubicin waε alεo included aε reference εubεtance. All compoundε were teεted in 3-6 different experimentε concentration dependently with,at leaεt, doublicate or triplicate inclubations per concentration tested. As can be seen from the results, BM 92.0700 is much better tolerated by the bone marrow stern cells compared to all other compounds tested, in particular, in comparison to 6-Mercaptopurinribosid. IC 50 values (μg/ml) for Azathioprine, 6-Mercaptopurine (6-MP), 6-Mercaptopurinribosid, BM 92.0729 and Doxorubicin in CFU-E and CFU-GM assays. 3 UBSTITUTESHEET(RULE26) Mean ± SEM; n, number of different experimentε Example 8 Bone marrow toxicity of BM 92.0729, Azathioprine, 6-Mercap- topurine and 6-Mercaptopurinriboεid in female Balb/c mice: Day + 4 (Exp. 930740) Exp. 930740 showε the bone marrow toxicity of BM 92.0792, Azathioprine, , 6-Mercaptopurine and 6-Mercaptopurinriboεid in vivo in female Balb/c mice which were treated once daily p.o. for four conεecutive days (day 0-day +3) . The animals were killed on day +4 and bone marrow cellularity (cells/femur) waε determined. The reεults indicate no bone marrow toxicity for the 6-Mercaptopurinriboεid ether lipid conjugate BM 92.0729 up to the higheεt doεe tested, i.e. 100 mg-kg "1 day "1 which correspondenz on a molar baεis with 30 mg-kg "1 day "1 of 6-Mercaptopurinribosid . This latter corn- pond showε, in contrast to the ether lipid conjugate BM 92.0792, clearly a dose-dependent reduciton in one marrow cellularity. The εame finding waε obtained for the other εubεtanceε, including Azathioprine and 6-Mercapto¬ purine . Bone marrow toxicity of BM 92.0729, Azathioprine, 6-Mercap- topurine and 6-Mercaptopurinribosid in female Balb/c mice: Day + 4 (Exp. 930740) mean + SEM; Treatment once daily p.o., day 0-day+3 Sacrifice on day +4 Mann- hitney-test Example 9 Bone marrow toxicity of BM 92.0729, Azathioprine, 6-Mercap¬ topurine, 6-Mercaptopurinribosid and Cyclosporin A in fe¬ male Balb/c mice: Day + 4 (Exp. 940026) . Exp. 940026 is an experiment which waε aimed at reproducing the results obtained in Exp. 930740 (Example 8) . In this experiment Cyclosporin A waε included aε a reference compo¬ und, too. The outcome of the Exp. 940026 confirmed the re- εultε obtained in Exp. 930740 in vivo. Bone marrow toxicity of BM 92.0729, Azathioprine, 6-Mercap- topurine, 6-Mercaptopurinribosid and Cyclosporin A in fe¬ male Balb/c mice: Day + 4 (Exp. 940026) mean + SEM; Treatment once daily p.o., day 0-day+3 Sacrifice on day +4 p < 0.05 Mann-Whitney-teεt p < 0.01 Example 10 Bone marrow toxicity (μM) of BM 92.0700 and 5-FU in CFU-E and CFU-GM aεεayε. The table shown in Encl . 4 giveε the mean IC 50 valueε for 5-Fluorouridine (5-FU) and the 5-FU ether lipid conjugate BM 92.0700 for bone marrow toxicity in vitro in CFU-E and CFU-GM aεεayε. For aεεay conditions, pleaεe refer to deεcription of Encl. 1. The data indicate that the ether lipid conjugate of 5-Fluo- rouridine BM 92.0700 iε 610 timeε and 238 timeε leεε toxic on erythrocyte and granulocyte/macrophage bone marrow stem cells, reεpectively, compared to 5-FU itεelf. Bone marrow toxicity (μM) of BM 92.0700 and 5-FU in CFU-E and CFU-GM assays Compound CFU-E a CFU-GM 3 BM 92.0700 0.372 (3) 1.178 (7) 610 x 238 x 5-FU 0.00061 (3) 0.00496 (10) a Mean; n, number of experiments Example 11 Influence of the 5-FU ether lipid conjugate BM 92.0700 (Fig. 1) and of 5-FU (Fig. 2) on the L 1210 leukemia in vivo: Survival time. Mice were inoculated with L 1210 leukemia cellε on day 0 (n = 10 animals/group) and were then treated once daily i.p. from day 0 (+lh) - day +41 (6 weeks) with the weekly cycles indicated on Encl. 5 and 6, respectively. From the survival curves of the control and treatment groups shown on Encl. 6 it is obvious, that 5-FU has, as reported in the literature, a very narrow dose-efficacy profile, i.e. icreasing the dose, for example from 2 x 10/5 x 0.1 mg-kg "1 day "1 to 2 x 10/5 x 0.3 mg-kg "1 day "1 or to even higher doseε lead to reduced εurvival rateε. In contraεt, with the 5-FU ether lipid conjugate BM 92.0700 a clear doεe-dependent increase in survival time was ob¬ tained compared to control I and II (Fig. 1) indicating that equimolar doεeε of BM 92.0700 are clearly more ef¬ fective in this leukemia model compared to the εtandard compound 5-FU. Taken into conεideration that BM 92.0700 iε more effective (Fig. 1 and 2) and much leεε toxic on bone marrow cellε it can be concluded that BM 92.0700 has a much higher thera¬ peutic index/ratio compared to the εtandard cytostatic 5-FU.

Claims: C L A I S Nucleoside monophosphate derivatives of for¬ mula (I) wherein R 1 may be a straight-chain or branched, satu- rated or unεaturated alkyl chain having 1-20 carbon atoms, optionally mono- or polysubstituted by halogen, Ci-Cg alkoxy, Cx-Cg alkylmercapto, Cτ_-Cg alkoxy¬ carbonyl, Ci-Cg alkylsulfinyl, or C^-Cg alkylsulfonyl groups; R 2 may be hydrogen, a straight-chain or bran¬ ched, saturated or unsaturated alkyl chain having 1-20 carbon atoms, optionally mono- or polysubεtituted by halogen, C -Cg alkoxy, C^-Cg alkylmercapto, C^-C alkoxycarbonyl, or C]_-Cg alkylsulfonyl groups; R 3 represents hydrogen, hydroxy, azido, amino, cyano, or halogen; repreεents hydroxy, azido, amino, cyano, or halogen,- R- repreεentε hydrogen, hydroxy, azido, amino, cyano, or halogen; X repreεentε a valence daεh, oxygen, sulfur, a sulfinyl or sulfonyl group; Y iε a valence daεh, an oxygen or εulfur atom; B represents a purine and/or pyrimidine baεe of formula III (a-d) wherein (Ilia) (lllb) 10 H N N N <χ- ~ N / ,8 N N N (lllc) (Mid) R 6 may be hydrogen,- an alkyl chain having 1-4 car¬ bon atomε, which may be εubεtituted by halogen; an al- kenyl and/or alkinyl residue having 2-6 carbon atomε, optionally εubstituted by halogen,- or halogen; R 6 ' may be a hydrogen atom or a benzyl or phenylthio residue; R 7 may be hydrogen; an alkyl chain having 1-4 car¬ bon atomε, which may be εubεtituted by halogen; or ha¬ logen,- R 8 may be hydrogen, an alkyl chain having 1-4 car¬ bon atomε, halogen, or a hydroxy or an amino group,- R 9 may be hydrogen, an amino group or a halogen atom; and R 1 ^ may be hydrogen, halogen, mercapto, hydroxy, Cχ-Cg alkoxy, C^-C alkylmercapto, or an amino group which may be mono- or diεubεtituted by C^-Cg alkyl, Ci-C alkoxy, hydroxy-C2~Cg alkyl, and/or C 3 -C5 cyclo¬ alkyl, aryl, hetaryl, aralkyl, or hetarylalkyl groupε, optionally εubstituted at the aryl or hetaryl reεidue by one or more mercapto, hydroxy, C^-Cg alkoxy, or C ^ -Cg alkyl groupε or halogen,- or C2~C alkenyl optionally substituted by mono- or dialkyl or alkoxy groups,- with the proviso that at least one of the reεi- dueε R 3 or R 5 iε hydrogen,- to their tautomerε, their optically active formε and racemic mixtureε, and to their phyεiologically ac¬ ceptable salts of inorganic and organic acids or baseε. 2. Nucleoside monophoεphate derivatives of for¬ mula I according to claim 1, characterized in that R 1 repreεentε a εtraight-chain Cg-Cι_5 alkyl group which may be εubstituted by a C^-Cg alkoxy or a C^-Cg alkylmer¬ capto group. 3. Nucleoside monophoεphate derivatives of for¬ mula I according to claim 1 or 2, characterized in that R 2 represents a straight-chain Cg-C 15 alkyl group which may further be εubstituted by a C^C alkoxy or a Cι_-Cg alkylmercapto group. 4 . Nucleoεide monophoεphate derivatives of for¬ mula I according to one of claimε 1-3, characterized in that X repreεents sulfur, εulfinyl or sulfonyl, and Y represents oxygen. 5. Nucleoside monophosphate derivativeε of for¬ mula I according to one of claimε 1-3, characterized in that X and Y repreεent a valence daεh, R 2 iε hydrogen, and R 1 represents a C 1 -C2 0 alkyl chain which optionally may be subεtituted by C]_-Cg alkoxy or a Cη_-Cg alkylmer¬ capto. 6. Nucleoεide monophoεphate derivativeε of for¬ mula I according to one of claimε 1-5, characterized in that R 5 repreεentε hydrogen, azido, cyano, or halogen. 7. Nucleoεide monophoεphate derivativeε of for¬ mula I according to one of claimε 1-6, characterized in that R 3 or R 4 repreεent a hydroxy, cyano or azido group or a halogen atom, wherein the reεidues may be the εame or different. 8. Nucleoεide monophoεphate derivativeε of for¬ mula I according to one of claimε 1-7, characterized in that R 6 and R 7 represent a hydrogen atom; a C^-Cg alkyl residue optionally εubεtituted by halogen; or a halogen atom; or a C2~Cg alkenyl or alkinyl group optionally εubstituted by halogen, wherein the residues may be the same or different. 9. Nucleoside monophosphate derivatives of for¬ mula I according to one of claims 1-8, characterized in r' θ ^ιtSHEET (RULE26) t h at R 8 represents a hydrogen atom, a Ci-C alkyl resi ¬ due, an amino group, or a halogen atom. 10 . Nucleoside monophosphate derivativeε of for¬ mula I according to one of claimε 1-9, characterized in that R 10 repreεentε a hydrogen or halogen atom, a Ci-C alkoxy, mercapto, Ci~C alkylmercapto, or an amino group which may be mono- or diεubεtituted by a Ci~Cg alkyl or a hydroxy-C 2 -Cg alkyl, or by a C 3 -Cg cycloalkyl, aryl or aralkyl reεidue, which optionally may further be subεtituted by one or more hydroxy, C -C alkoxy or C i ~C alkyl groups or by halogen atoms. 11. Nucleoside monophosphate derivatives of for¬ mula I according to one of claims 1-10, characterized in that R 1 represents a straight-chain Cg-Ci3 alkyl group optionally further substituted by a methoxy, ethoxy, butoxy, hexyloxy, methylmercapto, ethylmercapto, propylmercapto, butylmercapto, or hexylmercapto re¬ sidue,- R 2 representε a εtraight-chain Cg-C^ alkyl group optionally further εubstituted by a methoxy, ethoxy, propoxy, butoxy, hexyloxy, methylmercapto, ethylmer¬ capto, butylmercapto, or hexylmercapto reεidue; R 3 repreεentε a hydroxy, cyano, azido or fluorine reεidue; R 4 repreεentε a hydroxy, cyano, azido or fluorine reεidue; R 5 repreεentε hydrogen; R^ represents hydrogen, a methyl, trifluoromethyl, ethyl, vinyl, propenyl, ethinyl, propinyl residue, or a fluorine, chlorine or bromine atom; R 6 ' representε hydrogen,- R 7 repreεentε hydrogen, a methyl, ethyl, vinyl, propenyl, ethinyl, propinyl reεidue, or a chlorine or bromine atom,- and/or R 10 repreεentε hydrogen, a methoxy, ethoxy, propoxy, butoxy, hexyloxy, mercapto, methylmercapto, ethylmercapto, butylmercapto, hexylmercapto reεidue, an amino group optionally εubεtituted by thienyl, fu- ryl, pyridyl, thienylmethyl, furylmethyl, or pyrid- ylmethyl. 12. Nucleoεide monophoεphate derivativeε of formula I according to one of claimε 1-11 characterized in that the nucleoεide portion iε εelected from the following group: 6-mercaptopurine-9-β-D-ribof ranoεide, 5-fluorouridine, inosine, 5-methyluridine, 2 ' ,3 ' -dideεoxy-2 ' ,3 ' -difluoro- thymidine, 5-chlorouridine, 5-trifluoromethyluridine, 5-ethinyluridine, 5-ethinylcytidine, 5-prop-l-enyluri- dine, 5-prop-2-enyluridine, adenoεine, guanoεine, 2,6- diaminopurine-9-β-D-ribofuranoεide, 2-amino-6-mercapto¬ purine-9-β-D-ribofuranoεide, 2-amino-6-methylmercapto- purine-9-β-D-ribofuranoεide, 2-amino-6-chloropurine-9-β- D-ribofuranoεide, 2 ' -deεoxy-2 ' -aminoadenosine, 2 ' -deεoxy- 2 ' -azidoadenoεine, 2' -deεoxy-2 ' -azidocytidine, 2 ' -deεoxy- 5-fluorouridine, 2-chloroadenoεine, 2-fluoroadenoεine, 3' -deεoxy-5-fluoroadenoεine, 6-methylmercaptopurine-9-β- D-ribofuranoside, 2-bromoadenosine, 2-fluoro-2 ' -deεoxy- adenoεine. 13. A process for the preparation of nucleoside mo¬ nophoεphate derivatives of formula I according to one of claims 1-12, characterized by 1. reacting a compound of general formula V wherein R 1 , R 2 , X and Y have the meaningε aε in¬ dicated, with a compound of general formula VI wherein R 3 , R 4 , R 5 and B have the above men¬ tioned meanings, or represent a hydroxy group protected by an oxygen protecting group familiar to the artisan, in the presence of an activating acid chloride, such as 2,4, 6-triisopropylbenzenesulfonic acid chloride, and a tertiary nitrogen base, e.g., pyridine or lutidine, in an inert solvent, such as toluene, or immediately in anhydrous pyridine, and optionally, subsequent to hydro¬ lysis, removing the oxygen protecting groups according to procedures conventional in nucleoside chemistry, or reacting a compound of general formula VII hύT TIH UTE SHEET (RULE 26) wherein R 1 , R 2 , X and Y have the above-mentioned meanings, with a compound of general formula VI, wherein R 3 , R 4 , R 5 and B have the above-mentioned meanings, in the presence of phoεpholipaεe D from Streptomyces in an inert εolvent εuch as chloroform, in the presence of a εuitable buffer, and optionally, εubsequent to reaction, removing the oxygen protecting groups according to procedures conventional in nucleoside chemistry. 14. A drug, containing at least one compound of for¬ mula I according to one of claims 1-12, as well as phar¬ maceutical adjuvants or vehicles. 15. Use of compounds of formula I according to one of claims 1-12 for the preparation of drugs for the treatment of tumors or human diseaεeε.

Inventors: HERRMANN DIETER, MERTENS ALFRED, OPITZ HANS-GEORG, ZILCH HARALD, HERRMANN, DIETER, MERTENS, ALFRED, OPITZ, HANS-GEORG, ZILCH, HARALD
Applicants: BOEHRINGER MANNHEIM GMBH, HERRMANN DIETER, MERTENS ALFRED, OPITZ HANS GEORG, ZILCH HARALD, HERRMANN, DIETER, MERTENS, ALFRED, OPITZ, HANS-GEORG, ZILCH, HARALD
Application year: 1995
Main classification: C07H19
IPC codes: A61K31, A61P31, A61P35, A61P37, C07H19